The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Renato Martins
Honoraria - Genentech
Research Funding - Roche/Genentech
Upendra Parvathaneni
No relevant relationships to disclose
Anand K. Sharma
No relevant relationships to disclose
Luis E. Raez
Honoraria - OSI Pharmaceuticals; Roche/Genentech
Research Funding - Genentech
Michael A. Papagikos
No relevant relationships to disclose
Furhan Yunus
No relevant relationships to disclose
Julie E. Bauman
Research Funding - Genentech
Keith D. Eaton
No relevant relationships to disclose
Jay Justin Liao
No relevant relationships to disclose
Eduardo Mendez
No relevant relationships to disclose
Neal Futran
No relevant relationships to disclose
Brenda F Kurland
No relevant relationships to disclose
David X. Wang
No relevant relationships to disclose
Shawn Xiaoyu
No relevant relationships to disclose
Sarah G. Wallace
No relevant relationships to disclose
David N. Hayes
No relevant relationships to disclose